News & Events

All the latest news and events from PhoreMost

PhoreMost and XtalPi sign AI-based pharmaceutical drug discovery collaboration agreement
8th September 2020

PhoreMost and XtalPi sign AI-based pharmaceutical drug discovery collaboration agreement

Collaboration to rapidly develop high-quality leads from novel targets and sites identified by PhoreMost’s proprietary SITESEEKER platform XtalPi’s AI-based ID4 platform will explore ultra-large chemical spaces to discover novel inhibitors of protein-protein interaction sites PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, and XtalPi Inc., a …

PhoreMost appoints Dr Lorenz Mayr as Non-Executive Director
15th July 2019

PhoreMost appoints Dr Lorenz Mayr as Non-Executive Director

PhoreMost and inStem enter structural biology alliance
8th July 2019

PhoreMost and inStem enter structural biology alliance

PhoreMost and C4X Discovery announce neurodegeneration focused drug discovery collaboration
25th June 2019

PhoreMost and C4X Discovery announce neurodegeneration focused drug discovery collaboration

PhoreMost and Ligand Subsidiary Vernalis Limited Announce Drug Discovery Collaboration for Novel Oncology Target
12th June 2019

PhoreMost and Ligand Subsidiary Vernalis Limited Announce Drug Discovery Collaboration for Novel Oncology Target

PhoreMost and o2h discovery collaborate to progress first-in-class drug discovery programs
21st June 2018

PhoreMost and o2h discovery collaborate to progress first-in-class drug discovery programs

PhoreMost completes $15M (£11M) Series-A round to enter drug discovery
15th May 2018

PhoreMost completes $15M (£11M) Series-A round to enter drug discovery

Event

3rd Targeted Protein Degradation (TPD) Summit

13th to 15th October 2020